PT  - JOURNAL ARTICLE
AU  - H. IWASE
AU  - M. SHIMADA
AU  - T. TSUZUKI
AU  - Y. HORIUCHI
AU  - S. KUMADA
AU  - J HARUTA
AU  - T. YAMAGUCHI
AU  - M SUGIHARA
AU  - K INA
AU  - K. KUSUGAMI
AU  - S. GOTO
TI  - A Phase II Multicentric Trial of S-1 Combined with 24 h-infusion of Cisplatin in Patients with Advanced Gastric Cancer
DP  - 2005 Mar 01
TA  - Anticancer Research
PG  - 1297--1301
VI  - 25
IP  - 2B
4099  - http://ar.iiarjournals.org/content/25/2B/1297.short
4100  - http://ar.iiarjournals.org/content/25/2B/1297.full
SO  - Anticancer Res2005 Mar 01; 25
AB  - Background: The aim of this multicentric trial was to determine the clinical toxicities and antitumor effects of a chemotherapy regimen of S-1 combined with cisplatin in patients with inoperable locally or metastatic advanced gastric cancer. Patients and Methods: Forty-two patients were entered into the study. S-1 (80 mg/m2) was administered orally daily for 14 consecutive days and 24-h infusion of cisplatin (70 mg/m2) was administered on day 8 of every 28-day cycle. Results: The overall response rate was 50% and complete response rate was 5%. The most common adverse event was leucopenia, which occurred with grade 3 in 7 patients (16.6%) and grade 4 in 2 patients (4.8%). Non-hematological adverse events were generally mild. The median survival time was 342 days. The 2-year survival rate was 22.9%. Conclusion: This combination chemotherapy is active, convenient and well tolerated in patients with high-grade advanced gastric cancer. Copyright© 2005 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved